

Original Expiration Date: August 2, 2005
Applicant: Klaus P. Bogeso
Owner of Record: H. Lundbeck A/S
Title: Novel Intermediate and Method for Its Preparation
Classification: 549/467
Product Trade Name: CELEXA (citalopram hydrochloride)
Term Extended: 5 years

Any correspondence from applicant with respect to this matter should be addressed as follows:

Any correspondence with respect to this matter should be addressed as follows:

By mail: Commissioner for Patents
Mail Stop Patent Ext.
P.O. Box 1450
Alexandria, VA 22313-1450

OR By FAX: (703) 872-9411

Telephone inquiries related to this determination should be directed to the undersigned at (703) 306-3159.

/s/

Karin Ferriter
Senior Legal Advisor
Office of Patent Legal Administration
Office of the Deputy Commissioner
for Patent Examination Policy

cc: David T. Read RE: CELEXA (citalopram hydrochloride)
Acting Director Health Assessment Policy Staff, CDER FDA Docket No.: 98E-1221
Food and Drug Administration
1451 Rockville Pike, HFD-7
Rockville, MD 20852